| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/09/2011 | CA2782311A1 Method for removing cytokines from blood with surface immobilized polysaccharides |
| 06/09/2011 | CA2782285A1 Fexofenadine microcapsules and compositions containing them |
| 06/09/2011 | CA2782240A1 Formulations, salts and polymorphs of transnorsertraline and uses thereof |
| 06/09/2011 | CA2782204A1 Suppository for rectal, vaginal or urethral administration containing a probiotic, an antibiotic and an unsaturated non-esterified fatty acid |
| 06/09/2011 | CA2781923A1 Hypersulfated disaccharide formulations |
| 06/09/2011 | CA2781891A1 Novel tricyclic compounds |
| 06/09/2011 | CA2781823A1 Spiroindolinone pyrrolidines |
| 06/09/2011 | CA2781716A1 Multicyclic compounds and methods of use thereof |
| 06/09/2011 | CA2781661A1 Ship1 modulators and methods related thereto |
| 06/09/2011 | CA2781614A1 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
| 06/09/2011 | CA2781593A1 Microspheres of hydrolysed starch with endogenous, charged ligands |
| 06/09/2011 | CA2781493A1 Pharmaceutical compositions for the stimulation of stem cells |
| 06/09/2011 | CA2781487A1 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
| 06/09/2011 | CA2781254A1 Carboxyvinyl polymer-containing nanoparticle suspensions |
| 06/09/2011 | CA2781182A1 Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor |
| 06/09/2011 | CA2781140A1 Proline derivatives |
| 06/09/2011 | CA2780978A1 Soy protein-based nutritional formula with superior stability |
| 06/09/2011 | CA2780759A1 Protein kinase c inhibitors and uses thereof |
| 06/09/2011 | CA2780453A1 Treating xerophthalmia with compounds increasing meibomian gland secretion |
| 06/09/2011 | CA2780219A1 Azacyclic spiro derivatives |
| 06/09/2011 | CA2778675A1 Combination therapy for treating cancer and diagnostic assays for use therein |
| 06/09/2011 | CA2778586A1 Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| 06/09/2011 | CA2776724A1 Diphenyl azepine derivatives as monoamine reuptake inhibitors |
| 06/09/2011 | CA2724151A1 Novel derivatives of azabicyclo[3.2.0]hept-3-yl, their preparation process and the pharmaceutical compounds that contain them |
| 06/08/2011 | EP2330213A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 06/08/2011 | EP2330212A1 Novel compound ceramidastin, process for production thereof, and use thereof |
| 06/08/2011 | EP2330207A2 Transgenic plant-based methods for plant pests using RNAi |
| 06/08/2011 | EP2330194A2 Non-sequence complementary antiviral oligonucleotides |
| 06/08/2011 | EP2330129A2 Anti-TNF antibodies, compositions, methods and uses |
| 06/08/2011 | EP2330116A1 Replikin peptides and uses thereof |
| 06/08/2011 | EP2330115A1 Replikin peptides and uses thereof |
| 06/08/2011 | EP2330111A2 Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
| 06/08/2011 | EP2330107A2 Improved production method for adefovir dipivoxil |
| 06/08/2011 | EP2330105A1 Heteroaryl urea derivatives useful for inhibiting CHK1 |
| 06/08/2011 | EP2330104A1 Glucosyltransferase inhibitor comprising epigallocatechin gallate polymer as active ingredient |
| 06/08/2011 | EP2330103A1 Novel epigallocatechin gallate tetramer, and vascular endothelial function improver comprising same |
| 06/08/2011 | EP2330101A1 Process for making crystalline docetaxel |
| 06/08/2011 | EP2330099A1 Novel salt of morpholine derivative |
| 06/08/2011 | EP2330098A1 Compound with agitation effect on peroxisome proliferator-activated receptor , and preparation method and use thereof |
| 06/08/2011 | EP2330092A2 Medicament comprising steviol or isosteviol for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome |
| 06/08/2011 | EP2329862A1 Nitrate esters and their use for the treatment of muscle and muscle related diseases |
| 06/08/2011 | EP2329861A1 Pharmaceutical products and compositions comprising formoterol, budesonide and ipratropium |
| 06/08/2011 | EP2329849A1 Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| 06/08/2011 | EP2329848A1 Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes |
| 06/08/2011 | EP2329831A2 Stimulation of hair growth by Ginko biloba flavanoids |
| 06/08/2011 | EP2329830A2 Antisense inhibition of PTP1B expression |
| 06/08/2011 | EP2329829A2 Use of uridine in combination with choline for the treatment of memory disorders |
| 06/08/2011 | EP2329828A1 Tetracyclines for the treatment of ischaemia |
| 06/08/2011 | EP2329827A2 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| 06/08/2011 | EP2329826A1 Tetracyclines for the treatment of multiple sclerosis |
| 06/08/2011 | EP2329825A1 Method and composition for treating peripheral vascular diseases |
| 06/08/2011 | EP2329824A1 Novel pharmaceutical composition for treatment of nociceptive pain |
| 06/08/2011 | EP2329823A1 Method for improving absorbability of preparation, and preparation having improved absorbability |
| 06/08/2011 | EP2329822A1 Compositions and methods of treatment of cancer |
| 06/08/2011 | EP2329821A1 Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |
| 06/08/2011 | EP2329820A1 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof |
| 06/08/2011 | EP2329819A1 Pharmaceutical composition for use in treating sexually transmitted infections |
| 06/08/2011 | EP2329818A1 Combination therapy with PARP inhibitors |
| 06/08/2011 | EP2329817A1 Retinoic acid receptor antagonists, miR-10a inhibitors and inhibitors of HOXB1 or HOXB3 repressors for treating pancreatic cancer |
| 06/08/2011 | EP2329816A1 An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof |
| 06/08/2011 | EP2329815A1 A capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom |
| 06/08/2011 | EP2329813A1 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 06/08/2011 | EP2329811A1 Ocular implant obtained by multiple extrusion process |
| 06/08/2011 | EP2329810A1 Gastric retention drug delivery system, preparation method and use thereof |
| 06/08/2011 | EP2329717A1 Disinfectant and/or bactericidal aqueous compositions |
| 06/08/2011 | EP2329025A1 Periostin-induced pancreatic regeneration |
| 06/08/2011 | EP2329024A1 An endogenous short hairpin rna and the use of the same |
| 06/08/2011 | EP2329022A2 Method for obtaining oligonucleotide aptamers and uses thereof |
| 06/08/2011 | EP2328936A1 Hexadecasaccharides with antithrombotic activity, including a covalent bond and an amino chain |
| 06/08/2011 | EP2328935A1 Polysaccharides with antithrombotic activity, including a covalent bond and an amino chain |
| 06/08/2011 | EP2328903A1 Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use |
| 06/08/2011 | EP2328902A1 Pyrazolo [5,1-b]oxazole derivatives as crf1 antagonists |
| 06/08/2011 | EP2328898A1 2-heteroaryl-pyrrolo [3, 4-c]pyrrole derivatives and the use thereof as scd inhibitors |
| 06/08/2011 | EP2328897A1 Bicyclic heterocycle derivatives and their use as gpcr modulators |
| 06/08/2011 | EP2328896A1 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 06/08/2011 | EP2328895A1 New compounds ii |
| 06/08/2011 | EP2328893A1 Triazole compounds that modulate hsp90 activity |
| 06/08/2011 | EP2328892A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative |
| 06/08/2011 | EP2328891A1 New benzofurans suitable as precursors to compounds that are useful for imaging amyloid deposits |
| 06/08/2011 | EP2328890A1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| 06/08/2011 | EP2328889A1 Acetyl pyrrolidinyl indole derivative |
| 06/08/2011 | EP2328888A1 Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 06/08/2011 | EP2328887A1 Process for the preparation of esomeprazole magnesium in a stable form |
| 06/08/2011 | EP2328886A1 Derivatives of triazines and uracils, their preparation and their application in human therapeutics |
| 06/08/2011 | EP2328881A1 5-substituted benzoxazines |
| 06/08/2011 | EP2328879A2 Compounds, compositions and methods of using same for modulating uric acid levels |
| 06/08/2011 | EP2328878A1 Triazole compounds, the use thereof and preparations containing these compounds |
| 06/08/2011 | EP2328877A2 1,4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions |
| 06/08/2011 | EP2328876A1 Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists |
| 06/08/2011 | EP2328875A2 Targeted nitroxide agents |
| 06/08/2011 | EP2328874A2 Compounds, compositions and methods of using same for modulating uric acid levels |
| 06/08/2011 | EP2328873A2 Preparation of ranolazine |
| 06/08/2011 | EP2328872A1 Pyrazole compounds 436 |
| 06/08/2011 | EP2328871A2 Hedgehog pathway modulators |
| 06/08/2011 | EP2328869A2 Heteroaryl antagonists of prostaglandin d2 receptors |
| 06/08/2011 | EP2328868A1 Novel compounds active as muscarinic receptor antagonists |
| 06/08/2011 | EP2328867A1 Heterocyclic gpcr agonists |
| 06/08/2011 | EP2328866A1 3',6-substituted indirubins and their biological applications |
| 06/08/2011 | EP2328865A1 Hepatitis c virus inhibitors |
| 06/08/2011 | EP2328863A1 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof |